S&P Futures
4,075.25 -9.00 (-0.22%) Dow Futures
33,990.00 -56.00 (-0.16%) Nasdaq Futures
12,188.00 -34.25 (-0.28%) Russell 2000 Futures
1,914.80 -4.70 (-0.24%) Crude Oil
79.87 +0.19 (+0.24%) Gold
1,942.00 -3.60 (-0.19%)
Veracyte, Inc. (VCYT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 26.06 |
| Open | 25.61 |
| Bid | 24.37 x 1000 |
| Ask | 27.59 x 800 |
| Day's Range | 25.61 - 26.34 |
| 52 Week Range | 14.85 - 33.23 |
| Volume | |
| Avg. Volume | 923,909 |
| Market Cap | 1.868B |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.69 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VCYT
Related Research
- Veracyte, Inc.Daily – Vickers Top Buyers & Sellers for 06/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat8 months agoArgus Research
- Motley Fool
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
Veracyte (NASDAQ: VCYT) and Exact Sciences (NASDAQ: EXAS) focus on genomic tests to diagnose various cancers. A report by BIS Research puts the molecular cancer diagnostics market at $4.1 billion in 2022 but with a compound annual growth rate (CAGR) of 11.4% through 2032, reaching a $12.1 billion market by that time. Cancer is formed by changes to the genome in a body's cells, leading to uncontrollable growth.
- GlobeNewswire
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board. Dr. Nova currently serves as President of Veracyte's (Nasdaq: VCYT) U.S. CLIA business where
- Motley Fool
This Small-Cap Stock Is a No-Brainer Buy
This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.
